Mark Eccleston

WORK HISTORY

SKILLS

ABOUT MARK ECCLESTON

Recently completed role on the Scientific Advisory Board at VolitionRx. As a founding scientist, former Chief Technology Officer and previous Business Development Director this position reflects over 13 years experience with Volitions technology development including being named inventor on 25 volition patents.Working on an exciting drug repurposing project targeting NETosis, the rapid release of chromatin and granular proteins by Neutrophils to neutralise pathogens, which can become over-activated in viral and bacterial sepsis. The molecule is particularly interesting for viral sepsis, as seen in COVID-19, as it targets a pathway also involved in TMPRSS2 expression and viral protein production - a potential triple whammy for treating viral sepsis.Extensive experience in epigenetics both for diagnostic and therapeutic applications. Working on several novel biomarker technologies including an imaging biomarker for oncology therpaeutics and safety biomarker, again in oncology. In licensing of Antibodies and out licensing Research use kits for Volition’s Nucleosomics(TM) platform.Partner in 3 Innovate U.K. Grants focussed on novel Freeze drying analytical instrumentation designed for accelerated formulation development.Management of preclinical development programs for biological drugs, including a novel anti-gene system and a highly specific kinase inhibitor.Original background in organic and Polymer Chemistry with a speciality in biodegradable polymers for drug delivery. Specific focus has been on the use of responsive polymers that sense their local environmental conditions and respond through change in function. This technology has been applied to the disruption of intracellular membranes for delivery of biological drugs such as peptides and nucleic acid based systems (e.g. RNAi).I\'ve also consulted extensively in the field of responsive polymers in applications including bio-erodible chewing gum and degradable super-adsorbent polymers.I established a consultancy company, OncoLytika in 2010, to focus all my commercial activities. This will include consultancy work focussed on product innovation and project management. A contract with ValiRx was completed in 2011 as the company move into full clinical development. Our main client company is now VolitionRx, with OncoLytika providing management consultancy for collaborations as well as scientific input for their HyperGenomics technology platform.Specialties: Opportunity recognition and product inovation in therapeutic and diagnostic applications.